Expression signatures of TP53 mutations in serous ovarian cancers

BMC Cancer

Volumn 10, Issue , 2010, Pages 237-

  Bernardini, Marcus Q ^a   Baba, Tsukasa ^b   Lee, Paula S ^b   Barnett, Jason C ^b   Sfakianos, Gregory P ^b   Secord, Angeles A ^b   Murphy, Susan K ^b   Iversen, Edwin ^c   Marks, Jeffrey R ^b   Berchuck, Andrew ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Duke University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ACCURACY; ADVANCED CANCER; ARTICLE; CANCER STAGING; CANCER SURVIVOR; CONTROLLED STUDY; EARLY CANCER; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC CODE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; OVARY CANCER; PREDICTION; PREVALENCE;

ALGORITHMS; CLUSTER ANALYSIS; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVORS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952597892     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-237     Document Type: Article

References (33)

1. Havrilesky L, Darcy M, Hamdan H, Priore RL, Leon J, Bell J, Berchuck A. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2003, 21(20):3814-3825. 10.1200/JCO.2003.11.052, 14551300.
2. Leitao MM, Soslow RA, Baergen RN, Olvera N, Arroyo C, Boyd J. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol Oncol 2004, 93(2):301-306. 10.1016/j.ygyno.2004.01.043, 15099937.
3. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007, 211(1):26-35. 10.1002/path.2091, 17117391.
4. Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, Muto MG, Kindelberger D, Crum CP. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 2008, 26(25):4160-4165. 10.1200/JCO.2008.16.4814, 2654373, 18757330.
5. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001, 195(4):451-456. 10.1002/path.1000, 11745677.
6. Fallows S, Price J, Atkinson RJ, Johnston PG, Hickey I, Russell SE. P53 mutation does not affect prognosis in ovarian epithelial malignancies. J Pathol 2001, 194(1):68-75. 10.1002/path.857, 11329143.
7. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC, Berchuck A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991, 51(11):2979-2984.
8. Sood AK, Sorosky JI, Dolan M, Anderson B, Buller RE. Distant metastases in ovarian cancer: association with p53 mutations. Clin Cancer Res 1999, 5(9):2485-2490.
9. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005, 102(38):13550-13555. 10.1073/pnas.0506230102, 1197273, 16141321.
10. Troester MA, Herschkowitz JI, Oh DS, He X, Hoadley KA, Barbier CS, Perou CM. Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 2006, 6:276. 10.1186/1471-2407-6-276, 1764759, 17150101.
11. Cattoretti G, Rilke F, Andreola S, Damato L, Delia D. P53 expression in breast cancer. Int J Cancer 1988, 41:178-183. 10.1002/ijc.2910410204, 3276632.
12. Calza S, Hall P, Auer G, Bjohle J, Klaar S, Kronenwett U, Liu ET, Miller L, Ploner A, Smeds J, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 2006, 8(4):R34. 10.1186/bcr1517, 1779468, 16846532.
13. Ploner A, Miller LD, Hall P, Bergh J, Pawitan Y. Correlation test to assess low-level processing of high-density oligonucleotide microarray data. BMC Bioinformatics 2005, 6:80. 10.1186/1471-2105-6-80, 1084343, 15799785.
14. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990, 9(7):811-818. 10.1002/sim.4780090710, 2218183.
15. Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, Levine DA, Boyd J, Alonso MA, Secord AA, Bernardini MQ, et al. Microarray analysis of early stage serous ovarian cancers demonstrates profiles predictive of favorable outcome. Clin Cancer Res 2009, 15(7):2448-2455. 10.1158/1078-0432.CCR-08-2430, 19318476.
16. Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 2005, 11(10):3686-3696. 10.1158/1078-0432.CCR-04-2398, 15897565.
17. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006, 124(1):207-219. 10.1016/j.cell.2005.10.043, 16413492.
18. Otsubo T, Iwaya K, Mukai Y, Mizokami Y, Serizawa H, Matsuoka T, Mukai K. Involvement of Arp2/3 complex in the process of colorectal carcinogenesis. Mod Pathol 2004, 17(4):461-467. 10.1038/modpathol.3800062, 14990971.
19. Weinkauf M, Christopeit M, Hiddemann W, Dreyling M. Proteome- and microarray-based expression analysis of lymphoma cell lines identifies a p53-centered cluster of differentially expressed proteins in mantle cell and follicular lymphoma. Electrophoresis 2007, 28(23):4416-4426. 10.1002/elps.200600831, 17990259.
20. Li C, Lin M, Liu J. Identification of PRC1 as the p53 target gene uncovers a novel function of p53 in the regulation of cytokinesis. Oncogene 2004, 23(58):9336-9347. 10.1038/sj.onc.1208114, 15531928.
21. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007, 19(1):3-9. 10.1097/GCO.0b013e328011a21f, 17218844.
22. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007, 31(2):161-169. 10.1097/01.pas.0000213335.40358.47, 17255760.
23. Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El-Naggar A, Minguillon C, Schonborn I, et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001, 7(10):2984-2997.
24. Buller RE, Lallas TA, Shahin MS, Sood AK, Hatterman-Zogg M, Anderson B, Sorosky JI, Kirby PA. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer. Clin Cancer Res 2001, 7(4):831-838.
25. Shahin MS, Hughes JH, Sood AK, Buller RE. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 2000, 89(9):2006-2017. 10.1002/1097-0142(20001101)89:9<2006::AID-CNCR18>3.3.CO;2-Z, 11064359.
26. Song H, Xu Y. Gain of function of p53 cancer mutants in disrupting critical DNA damage response pathways. Cell Cycle 2007, 6(13):1570-1573.
27. Scian MJ, Stagliano KE, Deb D, Ellis MA, Carchman EH, Das A, Valerie K, Deb SP, Deb S. Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. Oncogene 2004, 23(25):4430-4443. 10.1038/sj.onc.1207553, 15077194.
28. Yan W, Liu G, Scoumanne A, Chen X. Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations. Cancer Res 2008, 68(16):6789-6796. 10.1158/0008-5472.CAN-08-0810, 2597213, 18701504.
29. Tan T, Chu G. p53 Binds and activates the xeroderma pigmentosum DDB2 gene in humans but not mice. Mol Cell Biol 2002, 22(10):3247-3254. 10.1128/MCB.22.10.3247-3254.2002, 133779, 11971958.
30. Hwang BJ, Toering S, Francke U, Chu G. p48 Activates a UV-damaged-DNA binding factor and is defective in xeroderma pigmentosum group E cells that lack binding activity. Mol Cell Biol 1998, 18(7):4391-4399. 109023, 9632823.
31. Hwang BJ, Ford JM, Hanawalt PC, Chu G. Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. Proc Natl Acad Sci USA 1999, 96(2):424-428. 10.1073/pnas.96.2.424, 15152, 9892649.
32. Fitch ME, Cross IV, Turner SJ, Adimoolam S, Lin CX, Williams KG, Ford JM. The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient human fibroblasts. DNA Repair 2003, 2(7):819-826. 10.1016/S1568-7864(03)00066-1, 12826282.
33. Kleivi K, Lind GE, Diep CB, Meling GI, Brandal LT, Nesland JM, Myklebost O, Rognum TO, Giercksky KE, Skotheim RI, et al. Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses. Mol Cancer 2007, 6:2. 10.1186/1476-4598-6-2, 1770935, 17201907.